Prostate cancer (PCa) is one of the most common male cancers in the Western world. Currently, early detection of PCa depends on an abnormal digital rectal examination and an elevated prostate-specific-antigen (PSA) level requiring a prostate biopsy, often associated with anxiety, discomfort, complications, and heavy expenses.

Quality of care varies greatly for the treatment of men with early-stage prostate cancer by region of the country and category of health care facility, suggesting the potential for improved patient outcomes with more standard treatment protocols, according to a new study that was published in the Aug. 1 issue of the Journal of Clinical Oncology.

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it has initiated a Phase 1 clinical trial for its Trofex molecular imaging program for the detection and staging of metastatic prostate cancer.

Men with prostate cancer and their partners face difficult decisions regarding treatment, and accurate information regarding expected outcomes can be hard to find, according to results of a multi-center study published Wednesday in the New England Journal of Medicine.

Researchers have identified a gene, known as OGR1, that suppresses prostate cancer metastasis in mice.

Researchers at the University of Michigan Comprehensive Cancer Center have identified a new imaging technique that can measure the effectiveness of treatment for prostate cancer that has spread to the bones. The technique involves measuring diffusion of water within tumors.